Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Trial Profile

Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ixazomib (Primary) ; Asparaginase; Asparaginase; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Hydrocortisone; Methotrexate; Vincristine
  • Indications Acute lymphoblastic leukaemia; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Results assessing safety of ixazomib combined with VXLD (n=5) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 24 Aug 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top